Brian Taylor Slingsby - Jul 12, 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director, 10%+ Owner
Signature
Brian Taylor Slingsby by: /s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Jul 12, 2023
Transactions value $
$0
Form type
4
Date filed
7/14/2023, 08:55 AM
Previous filing
Feb 16, 2023
Next filing
May 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Other $0 -44K -100% $0.00* 0 Jul 12, 2023 Common Stock 44K $16.00 Direct F1, F2
transaction MLYS Stock Option Other $0 +88K $0.00 88K Jul 12, 2023 Common Stock 88K $16.00 See footnote F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options transferred pursuant to an option transfer agreement between Brian Taylor Slingsby and Catalys Pacific Fund, LP.
F2 The stock option vests in 36 monthly installments beginning on March 9, 2023.
F3 Represents stock options transferred pursuant to option transfer agreements between Catalys Pacific Fund, LP and each of Brian Taylor Slingsby and Takeshi Takahashi.
F4 Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.